
As the coronavirus spread across more and more of the world, Danish diagnostics business Bioporto encountered more and more challenges. The company had 10 clinical studies underway at US hospitals, but they were shut down, and the FDA approval that was expected has been delayed again.
Bioporto's US sales organization was cut down to the bone. It became impossible to get access to Danish hospitals, and CEO Peter Mørch was forced to cancel his business trips.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app